Revvity Expands into Type 1 Diabetes Screening with IVDR-Certified Kit — Revvity, Inc.

Event summary

Revvity launched the GSP® T1D 3plex kit, a CE-IVDR-certified solution for early detection of Type 1 Diabetes (T1D).
The kit enables population-wide screening using capillary dried blood spots (DBS) and is processed on Revvity’s GSP® instrument.
The solution is designed for emerging national T1D screening programs and will initially be available in Europe and markets accepting CE IVD-marked products.
Revvity will present details on its T1D solutions at the European Association for the Study of Diabetes (EASD) conference in Milan from September 28 – October 2, 2026.

The big picture

Revvity’s launch of the GSP® T1D 3plex kit marks a strategic expansion into child health screening, leveraging its expertise in newborn screening. This move aligns with broader industry trends toward early disease detection and preventive healthcare, potentially positioning Revvity as a key player in the growing diagnostics market. With 2025 revenue of $2.9 billion, the company is well-positioned to scale this solution across global markets.

What we're watching

Market Adoption: The pace at which European markets adopt the GSP® T1D 3plex kit for national screening programs.
Regulatory Expansion: Whether Revvity can secure FDA clearance to enter the U.S. market with this solution.
Strategic Partnerships: How the collaboration with Sanofi will influence the development and deployment of T1D screening solutions.